Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Silver Trust (SLV) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

iShares Silver TrustTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

iShares Silver Trust vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Silver Trust trades at $58.95, while State Street SPDR S&P Biotech ETF trades at $159.08. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals.

SLVXBI
52-Week High
$105.57$164.28
52-Week Low
$33.89$86.92
Sector
Broad Market / Factor

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Silver Trust

SLV trades at $59.45, showing minimal daily movement with a 0.07% gain. The technical outlook is bullish with strong moving average support, though RSI levels suggest potential overbought conditions near-term. Recent news highlights silver's rebound driven by data center demand and Fed policy expectations, with the metal recovering from earlier 2026 declines.

Silver's investment case remains compelling due to structural supply constraints and growing industrial demand, particularly from technology sectors. Key risks include Federal Reserve policy uncertainty and dollar strength, while technical resistance near $60 presents immediate price challenges. The metal's volatility requires careful position sizing despite positive long-term fundamentals.

State Street SPDR S&P Biotech ETF

XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.

Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Silver Trust

The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.

Read more on SLV

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI